Arbutus Biopharma Corporation ABUS EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Arbutus Biopharma Corporation’s reported figures.
Based on trailing twelve months.
The official record: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arbutus Biopharma Corporation's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arbutus Biopharma Corporation's EBITDA margin?
- Arbutus Biopharma Corporation (ABUS) reported EBITDA margin of 81.8% in Q1 2026.
- How has Arbutus Biopharma Corporation's EBITDA margin changed year-over-year?
- Arbutus Biopharma Corporation's EBITDA margin increased by 106.4% year-over-year, from -1,269.5% to 81.8%.
- What is the long-term trend for Arbutus Biopharma Corporation's EBITDA margin?
- Over 5 years (2020 to 2025), Arbutus Biopharma Corporation's EBITDA margin has grown at a -19.8% compound annual growth rate (CAGR), from -807.4% to -267.8%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.